Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites

被引:29
|
作者
Iketani, Sho [1 ,2 ]
Hong, Seo Jung [3 ]
Sheng, Jenny [3 ,4 ]
Bahari, Farideh [5 ]
Culbertson, Bruce [4 ,6 ]
Atanaki, Fereshteh Fallah [5 ]
Aditham, Arjun K. [7 ]
Kratz, Alexander F. [3 ,4 ]
Luck, Maria, I [1 ,8 ]
Tian, Ruxiao [2 ]
Goff, Stephen P. [1 ,2 ,9 ]
Montazeri, Hesam [5 ]
Sabo, Yosef [1 ,8 ]
Ho, David D. [1 ,2 ,8 ]
Chavez, Alejandro [3 ]
机构
[1] Columbia Univ, Aaron Diamond AIDS Res Ctr, Vagelos Coll Phys & Surg, New York, NY USA
[2] Columbia Univ, Dept Microbiol & Immunol, Vagelos Coll Phys & Surg, New York, NY USA
[3] Columbia Univ, Dept Pathol & Cell Biol, Vagelos Coll Phys & Surg, New York, NY 10027 USA
[4] Columbia Univ, Irving Med Ctr, Integrated Program Cellular Mol & Biomed Studies, New York, NY USA
[5] Univ Tehran, Inst Biochem & Biophys, Dept Bioinformat, Tehran, Iran
[6] Columbia Univ, Med Scientist Training Program, Irving Med Ctr, New York, NY USA
[7] Fred Hutchinson Canc Res Ctr, Basic Sci Div, Seattle, WA 98104 USA
[8] Columbia Univ, Dept Med, Div Infect Dis, Vagelos Coll Phys & Surg, New York, NY USA
[9] Columbia Univ, Dept Biochem & Mol Biophys, Vagelos Coll Phys & Surg, New York, NY USA
关键词
CORONAVIRUS 3C-LIKE PROTEASE; DIMER INTERFACE; SARS; DIMERIZATION; PROTEINASE; MUTATIONS; PROGRESS; ESCAPE; YEAST;
D O I
10.1016/j.chom.2022.08.003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The SARS-CoV-2 3CL protease (3CL(pro)) is an attractive therapeutic target, as it is essential to the virus and highly conserved among coronaviruses. However, our current understanding of its tolerance to mutations is limited. Here, we develop a yeast-based deep mutational scanning approach to systematically profile the activity of all possible single mutants of the 3CL(pro) and validate a subset of our results within authentic viruses. We reveal that the 3CL(pro) is highly malleable and is capable of tolerating mutations throughout the protein. Yet, we also identify specific residues that appear immutable, suggesting that these may be targets for future 3CL(pro) inhibitors. Finally, we utilize our screening as a basis to identify E166V as a resistance-conferring mutation against the clinically used 3CL(pro) inhibitor, nirmatrelvir. Collectively, the functional map presented herein may serve as a guide to better understand the biological properties of the 3CL(pro) and for drug development against coronaviruses.
引用
收藏
页码:1354 / +
页数:15
相关论文
共 50 条
  • [21] In silico screening of potential compounds from begonia genus as 3CL protease (3Cl pro) SARS-CoV-2 inhibitors
    Maulana, Saipul
    Wahyuni, Tutik Sri
    Widiyanti, Prihartini
    Zubair, Muhammad Sulaiman
    JOURNAL OF PUBLIC HEALTH IN AFRICA, 2023, 14
  • [22] Virtual Screening of Chinese Medicine Small Molecule Compounds Targeting SARS-CoV-2 3CL Protease (3CL pro)
    He, Qingxiu
    Chen, Xin
    Yang, Xi
    Li, Guangpin
    Gu, Haiqiong
    Chu, Han
    Lin, Zhihua
    Wang, Yuanqiang
    LETTERS IN DRUG DESIGN & DISCOVERY, 2021, 18 (04) : 355 - 364
  • [23] Inhibition of SARS-CoV 3CL protease by flavonoids
    Jo, Seri
    Kim, Suwon
    Shin, Dong Hae
    Kim, Mi-Sun
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2020, 35 (01) : 145 - 151
  • [24] Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor
    Katsube, Takayuki
    Kezbor, Safwan
    Shimizu, Ryosuke
    Kubota, Ryuji
    INFECTIOUS DISEASES AND THERAPY, 2024, 13 (03) : 597 - 607
  • [25] Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening
    Zhu, Wei
    Xu, Miao
    Chen, Catherine Z.
    Guo, Hui
    Shen, Min
    Hu, Xin
    Shinn, Paul
    Klumpp-Thomas, Carleen
    Michael, Samuel G.
    Zheng, Wei
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2020, 3 (05) : 1008 - 1016
  • [26] Capillary electrokinetic chromatography for chiral separation of potential SARS-CoV-2 3CL protease inhibitors
    Brier, Lucile
    Furman, Christophe
    Charton, Julie
    Deprez, Benoit
    Lipka, Emmanuelle
    ELECTROPHORESIS, 2024, 45 (11-12) : 1010 - 1017
  • [27] Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance
    Ip, Jonathan Daniel
    Chu, Allen Wing-Ho
    Chan, Wan-Mui
    Leung, Rhoda Cheuk-Ying
    Abdullah, Syed Muhammad Umer
    Sun, Yanni
    To, Kelvin Kai -Wang
    EBIOMEDICINE, 2023, 91
  • [28] In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease
    Xiong, Muya
    Nie, Tianqing
    Shao, Qiang
    Li, Minjun
    Su, Haixia
    Xu, Yechun
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 231
  • [29] Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model
    Fukao, Keita
    Nobori, Haruaki
    Kuroda, Takayuki
    Baba, Kaoru
    Matsumoto, Kazumi
    Tanaka, Yukari
    Tachibana, Yuki
    Kato, Teruhisa
    Shishido, Takao
    VIRUSES-BASEL, 2023, 15 (10):
  • [30] Biochemical and structural characterization of second-generation inhibitors targeting the SARS-CoV-2 3CL protease
    Muczynski, Michael
    Engel, Joseph
    Amblard, Franck
    Patel, Dharmeshkumar
    Schinazi, Raymond
    Kovari, Ladislau
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2024, 300 (03) : S180 - S180